Holen Sie sich die Stockscreener-App
39.45
1.15%
-0.46
Vorhandelsmarkt:
39.55
0.10
+0.25%
Schlusskurs vom Vortag:
$39.91
Offen:
$39.28
24-Stunden-Volumen:
894.02K
Relative Volume:
0.94
Marktkapitalisierung:
$4.14B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-8.21%
1M Leistung:
+33.28%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$37.00
$40.04
1-Wochen-Bereich:
$37.00
$47.40
52-Wochen-Spanne:
$12.30
$47.40
Metsera Inc Stock (MTSR) Company Profile
Firmenname
Metsera Inc
Sektor
Branche
Telefon
(212) 784-6595
Adresse
3 WORLD TRADE CENTER, NEW YORK
Vergleichen Sie MTSR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
39.45 | 4.52B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-02-25 | Eingeleitet | BofA Securities | Buy |
| 2025-02-25 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-25 | Eingeleitet | Guggenheim | Buy |
Metsera Inc Aktie (MTSR) Neueste Nachrichten
Metsera Inc. Stock Analysis and ForecastHigh-margin investment plays - jammulinksnews.com
What drives Metsera Inc. stock priceFree Advanced Stock Screener Access - jammulinksnews.com
What analysts say about Metsera Inc. stockFree Consultation - jammulinksnews.com
Is Metsera Inc. a good long term investmentFree High-Return Strategy Alerts - jammulinksnews.com
Metsera price target raised to $45 from $38 at BofA - TipRanks
Metsera, Inc.: Buy Rating Affirmed Amid Promising Clinical Data and Strategic Positioning - TipRanks
ATAI Impresses, CDTX Navigates With Confidence, MTSR Builds Momentum, COGT Keeps Scaling The Summit… - RTTNews
Metsera soars 75% after InvestingPro’s April undervalued signal By Investing.com - Investing.com Nigeria
Metsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes Association - MSN
Why Metsera Inc. stock attracts strong analyst attentionFast Gains With Reduced Risk - Newser
What makes Metsera Inc. stock price move sharplyLow Risk Profit Ideas - Newser
How Metsera Inc. stock performs during market volatility2x Return Forecast - Newser
Metsera Inc. (MTSR) Is a Great Choice for 'Trend' Investors, Here's Why - sharewise.com
Wall Street Analysts See a 55.72% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? - Yahoo Finance
Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? - Yahoo Finance
Metsera, Inc.(NasdaqGS: MTSR) added to S&P Biotechnology Select Industry Index - MarketScreener
Metsera (NASDAQ:MTSR) Now Covered by Analysts at Wells Fargo & Company - Defense World
Metsera stock initiated at overweight by Wells Fargo on obesity drug - Investing.com Nigeria
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results - MSN
Cantor Fitzgerald reiterates Metsera stock rating on strong MET-233i results - Investing.com Nigeria
Promising Results Of Amylin Analogs In Obesity: Metsera Case Review (NASDAQ:MTSR) - Seeking Alpha
Cantor Fitzgerald Predicts Metsera FY2026 Earnings - Defense World
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Metsera Shows Rising Price Performance With Jump To 92 RS Rating - MSN
Finanzdaten der Metsera Inc-Aktie (MTSR)
Es liegen keine Finanzdaten für Metsera Inc (MTSR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):